Video

A targeted therapy for breast cancer that specifically targets and blocks the HER2 protein, which is over-expressed in about 20-30% of breast cancers. These antibodies work by interfering with HER2's ability to send growth signals, slowing or stopping the growth of HER2-positive tumors. 

Combination of monoclonal antibodies targeting Nipah virus glycoproteins, particularly the G and F glycoproteins, which are crucial for viral entry and fusion. These antibodies can be used for both therapeutic and prophylactic purposes